Since we observed gasdermin B expression post-IFN-γ treatment in CRC cells, and because we found that elraglusib treatment upregulated immune cell IFN-γ secretion, we hypothesize that the IFN-γ released from CD8+ T cells and NK cells is responsible for triggering pyroptosis, which may contribute to elraglusib-mediated immunostimulation. The gene discussed is GSDMB; the disease is colorectal carcinoma.